ID: ALA1085865
PubChem CID: 46864280
Max Phase: Preclinical
Molecular Formula: C15H29N7O5
Molecular Weight: 387.44
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(N)=O)[C@@H](C)O
Standard InChI: InChI=1S/C15H29N7O5/c1-7(20-9(3)24)13(26)21-10(5-4-6-19-15(17)18)14(27)22-11(8(2)23)12(16)25/h7-8,10-11,23H,4-6H2,1-3H3,(H2,16,25)(H,20,24)(H,21,26)(H,22,27)(H4,17,18,19)/t7-,8+,10-,11-/m0/s1
Standard InChI Key: CYECJCHCQBPTIK-OEIWMXHLSA-N
Molfile:
RDKit 2D
27 26 0 0 1 0 0 0 0 0999 V2000
7.8069 -5.7002 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.8069 -4.5002 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7675 -3.9006 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
9.1069 -3.7502 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.1038 -2.2494 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.8030 -1.5008 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7648 -2.1026 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
7.7999 0.0000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.5000 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.2000 0.0000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9000 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6000 0.0000 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.3000 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2606 0.1503 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.3000 1.9500 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
9.0999 0.7500 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.3999 0.0000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.3999 -1.2000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
11.6999 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.6999 1.9500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.9999 0.0000 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.2999 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.3393 0.1503 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
14.2999 1.9500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.4078 -4.4988 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.4102 -5.6988 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
11.4459 -3.8970 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 1
2 3 1 0
2 4 1 0
4 5 1 6
5 6 1 0
6 7 2 0
6 8 1 0
8 9 1 6
9 10 1 0
10 11 1 0
11 12 1 0
12 13 1 0
13 14 2 0
13 15 1 0
8 16 1 0
16 17 1 0
17 18 2 0
17 19 1 0
19 20 1 6
19 21 1 0
21 22 1 0
22 23 2 0
22 24 1 0
4 25 1 0
25 26 2 0
25 27 1 0
M END| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 387.44 | Molecular Weight (Monoisotopic): 387.2230 | AlogP: -3.39 | #Rotatable Bonds: 11 |
| Polar Surface Area: 212.52 | Molecular Species: BASE | HBA: 6 | HBD: 8 |
| #RO5 Violations: 1 | HBA (Lipinski): 12 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 11.88 | CX Basic pKa: 11.62 | CX LogP: -4.61 | CX LogD: -6.59 |
| Aromatic Rings: ┄ | Heavy Atoms: 27 | QED Weighted: 0.10 | Np Likeness Score: 0.16 |
| 1. Karatas H, Townsend EC, Bernard D, Dou Y, Wang S.. (2010) Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction., 53 (14): [PMID:20575550] [10.1021/jm100139b] |
| 2. (2016) Inhibition of WDR5 interaction with its binding partners, |
| 3. Karatas, Hacer H, Townsend, Elizabeth C EC, Bernard, Denzil D, Dou, Yali Y and Wang, Shaomeng S. 2010-07-22 Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. [PMID:20575550] |
| 4. Bolshan, Yuri Y and 16 more authors. 2013-03-14 Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction. [PMID:24900672] |
| 5. Getlik, Matthäus M and 17 more authors. 2016-03-24 Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). [PMID:26958703] |
| 6. Li, Dong-Dong DD and 9 more authors. 2016-08-08 Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. [PMID:27116709] |
| 7. Li, Dong-Dong DD and 8 more authors. 2016-11-29 High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. [PMID:27598236] |
| 8. Li, Dong-Dong DD and 5 more authors. 2016-11-15 Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. [PMID:27720555] |
| 9. Wang, Feng F and 17 more authors. 2018-07-12 Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:29889518] |
| 10. Ye, Xiaoqing X and 11 more authors. 2019-02-15 The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening. [PMID:30626558] |
| 11. Tian, Jianhua and 24 more authors. 2020-01-23 Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. [PMID:31858797] |
| 12. Chacón Simon, Selena and 14 more authors. 2020-04-23 Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:32223236] |
Source(2):